Loading stock data…
Pfizer, Inc. (PFE)
$28.45-0.36 (-1.25%)
Market ClosedLast close Sep 4
Pfizer Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pfizer Inc. in the Healthcare sector is trading at $28.45 with a market capitalization of $159.7B. Wall Street consensus targets $28.61 (26 analysts), implying a +0.5% move over the next 12 months. The stock is currently near its 52-week high of $29.21, remaining 11.8% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.03B↑ | $14.45B↓ | $17.56B↑ | $16.65B↑ | $14.65B |
| Gross Profit | $10.94B↑ | $10.90B↓ | $12.29B↓ | $12.48B↑ | $10.88B |
| Operating Income | $3.54B↓ | $4.27B↑ | $3.69B↓ | $5.53B↑ | $3.77B |
| Net Income | -$248.00M↓ | $2.69B↑ | -$1.65B↓ | $3.54B↑ | $2.91B |
Peer Comparison
JNJUNHABBV
Fundamentals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$159.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
36.86
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
6.05%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.09%
Volume
Today's trading volume
23.53M
Recent News
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.
Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.